Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip V Kaye

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Microorganisms|February 5, 2021
Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against <i>Clostridioides difficile</i>Cansu Karyal, Jaime Hughes, Michelle L Kelly, et al.
Histopathology|December 21, 2010
Novel staining pattern of p53 in Barrett's dysplasia--the absent patternPhilip V Kaye, Syeda A Haider, Peter D James, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|February 25, 2020
The management and long-term outcomes of endoscopic and surgical treatment of early esophageal adenocarcinomaJohn H Saunders, Samim Al-Zubaidi, Ruth C Waller, et al.
Histopathology|May 15, 2009
Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistryPhilip V Kaye, Syeda A Haider, Mohammed Ilyas, et al.
Histopathology|February 27, 2016
Dysplasia in Barrett's oesophagus: p53 immunostaining is more reproducible than haematoxylin and eosin diagnosis and improves overall reliability, while grading is poorly reproduciblePhilip V Kaye, Mohammad Ilyas, Irshad Soomro, et al.
Gastroenterology|August 23, 2008
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitisGuruprasad P Aithal, James A Thomas, Philip V Kaye, et al.
Gut|March 29, 2024
National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett's oesophagus and stage I oesophageal adenocarcinomaMassimiliano di Pietro, Nigel J Trudgill, Melina Vasileiou, et al.
Gut|April 12, 2014
The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagusMassimiliano di Pietro, David F Boerwinkel, Mohammed Kareem Shariff, et al.
Gut|October 30, 2013
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagusRebecca C Fitzgerald, Massimiliano di Pietro, Krish Ragunath, et al.
Gut|November 29, 2019
British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelinesMatthew D Rutter, James East, Colin J Rees, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Microorganisms|February 5, 2021
Colonisation Factor CD0873, an Attractive Oral Vaccine Candidate against <i>Clostridioides difficile</i>Cansu Karyal, Jaime Hughes, Michelle L Kelly, et al.
Histopathology|December 21, 2010
Novel staining pattern of p53 in Barrett's dysplasia--the absent patternPhilip V Kaye, Syeda A Haider, Peter D James, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|February 25, 2020
The management and long-term outcomes of endoscopic and surgical treatment of early esophageal adenocarcinomaJohn H Saunders, Samim Al-Zubaidi, Ruth C Waller, et al.
Histopathology|May 15, 2009
Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistryPhilip V Kaye, Syeda A Haider, Mohammed Ilyas, et al.
Histopathology|February 27, 2016
Dysplasia in Barrett's oesophagus: p53 immunostaining is more reproducible than haematoxylin and eosin diagnosis and improves overall reliability, while grading is poorly reproduciblePhilip V Kaye, Mohammad Ilyas, Irshad Soomro, et al.
Gastroenterology|August 23, 2008
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitisGuruprasad P Aithal, James A Thomas, Philip V Kaye, et al.
Gut|March 29, 2024
National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett's oesophagus and stage I oesophageal adenocarcinomaMassimiliano di Pietro, Nigel J Trudgill, Melina Vasileiou, et al.
Gut|April 12, 2014
The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett's oesophagusMassimiliano di Pietro, David F Boerwinkel, Mohammed Kareem Shariff, et al.
Gut|October 30, 2013
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagusRebecca C Fitzgerald, Massimiliano di Pietro, Krish Ragunath, et al.
Gut|November 29, 2019
British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelinesMatthew D Rutter, James East, Colin J Rees, et al.
Pageof 2